Innovent Biologics, Inc. is a biopharmaceutical company founded in 2011 that develops, manufactures, and commercializes biologics. The company operates an integrated platform covering research, discovery, development, CMC, and commercialization to build a pipeline of monoclonal antibodies and other drug assets. Its therapeutic focus includes cancer, cardiovascular and metabolic diseases, autoimmune disorders, and eye diseases. Innovent generates revenue from the sale of pharmaceutical products, license fees, and R&D service fees. The company serves markets in China and internationally, utilizing strategic collaborations and partnerships to advance its drug candidates. It maintains manufacturing facilities to ensure product quality and supply. The business model involves both internal development and licensing arrangements with global partners.

Summarised from the company's own disclosures, fiscal year ended Apr 2026

Industry Biotechnology Homepage innoventbio.com
Sector Healthcare IR page investor.innoventbio.com/en/investors
Tags
monoclonal antibodies, oncology, cardiovascular and metabolic diseases, autoimmune diseases, ophthalmology, biologics, drug discovery, clinical development, cmc, licensing, r&d services, Xinbimin, Tiptofab, IBI363, TAK-928
Press page —

Metrics

Valuation  
Market cap HK$ 149.35B
Market cap (USD) $ 19.033B
P/E 157.25
PEG —
P/BV 6.07
P/S 8.08
P/OCF 9.56
P/FCF —
Dividend yield —
Turnover / mcap 0.48%
Returns  
ROE 5.0%
ROI 4.0%
ROIC 4.0%
Profit margin 6.2%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 2.5%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score 23.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Revenue 13.042B 9.422B 6.206B 4.556B 4.27B 3.844B 1.048B 9.477M 18.538M
Net profit 813.565M -94.631M -1.028B -2.179B -3.138B -998.421M -1.72B -5.771B -562.318M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Share price 70.48 32.14 35.83 27.52 33.27 81.13 25.11 — —
Price performance 12m 1.24 -0.1 0.23 -0.21 -0.56 2.24 — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

Innovent Biologics, Inc. (ticker 1801), listed in Hong Kong.

ETFs Holding Innovent Biologics, Inc.

ETF Weight in ETF Shares Market value As of
OZEM 1.86% 95,000 $ 1.039M Nov 17, 2026
MCH 1.66% 38,000 $ 385.715K Jun 30, 2026
NBCE 1.13% 15,600 $ 206.582K Aug 31, 2026
PCCE 0.98% 1,500 $ 15.225K Jun 30, 2026
MINV 0.79% 144,000 $ 1.462M Jun 30, 2026
TDI 0.68% 241,374 $ 2.45M Jun 30, 2026
EMKT 0.60% 107,500 $ 1.091M Jun 30, 2026
MCHS 0.49% 12,000 $ 121.805K Jun 30, 2026
MEMA 0.48% 4,500 $ 59.584K Aug 31, 2026
AVSE 0.28% 56,000 $ 594.163K Nov 16, 2026
CGNG 0.26% 700,500 $ 7.49M Nov 16, 2026
AVEM 0.25% 6,327,000 $ 67.13M Nov 16, 2026
REMG 0.17% 17,500 $ 177.614K Jun 30, 2026
DFSE 0.11% 58,000 $ 643.98K Nov 12, 2026
DFAE 0.08% 678,500 $ 7.533M Nov 12, 2026
NTSE 0.07% 4,000 $ 40.602K Jun 30, 2026
DFEM 0.05% 371,000 $ 4.119M Nov 12, 2026
JSTC 0.02% 5,459 $ 58.376K Nov 17, 2026
DFAX 0.01% 85,000 $ 943.764K Nov 12, 2026